Management ChangeOct 9, 2026, 04:16 PM
Virax Biolabs Eliminates COO Role; Dr. McCracken Departs
AI Summary
Virax Biolabs Group Ltd. announced a restructuring of its senior management to streamline operations and reduce costs, which includes eliminating the Chief Operating Officer role. Consequently, Dr. Nigel McCracken's position as COO has been made redundant, with his employment ending on December 23, 2026, though he will continue as a director. Dr. McCracken will receive statutory redundancy pay and payment in lieu of notice. Concurrently, Clement Monteil has been appointed Acting Chief Scientific Officer for a six-month term.
Key Highlights
- Virax Biolabs Group Ltd. is eliminating the standalone role of Chief Operating Officer as part of a restructuring.
- Dr. Nigel McCracken, COO, will have his position made redundant, commencing paid garden leave on October 5, 2026.
- Dr. McCracken's employment terminates effective December 23, 2026, but he will remain a director.
- Dr. McCracken will receive a statutory redundancy payment of £3,379.50 and payment in lieu of notice.
- Clement Monteil appointed Acting Chief Scientific Officer for an initial six-month term, effective October 5, 2026.
Price Impact
More from VRAX